BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2015 5:56:00 PM | Browse: 413 | Download: 529
Publication Name World Journal of Gastroenterology
Manuscript ID 10318
Country of Manuscript Source United States
Received
2014-03-26 08:30
Peer-Review Started
2014-03-26 16:42
To Make the First Decision
2014-04-28 14:13
Return for Revision
2014-05-03 19:35
Revised
2014-07-31 07:07
Second Decision
2014-09-19 08:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-09-19 09:33
Articles in Press
2014-09-19 10:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-01-29 18:24
Publish the Manuscript Online
2015-02-11 17:56
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript type Systematic Review
Article Title Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review
Manuscript Source Unsolicited Manuscript
All Author List Michael S Broder, David Beenhouwer, Jonathan R Strosberg, Maureen P Neary and Dasha Cherepanov
Funding Agency and Grant Number
Funding Agency Grant Number
Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080, United States
Correspondence To Michael S Broder, MD, MSHS, Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, Beverly Hills, CA 90212, United States. mbroder@pharllc.com
Keywords Carcinoma; Neuroendocrine; Carcinoid syndrome; Carcinoid tumor; Gastrointestinal neoplasms; Neuroendocrine tumor; Antineoplastic agents; Hormonal; Dose-Response relationship; Drug; Octreotide; Literature review; Efficacy; Effectiveness; Symptom control; Tumor progression control; Diarrhea; Abdominal pain; Flushing
Core Tip Although octreotide-long-acting repeatable (LAR) is Food and Drug Administration approved for alleviating severe diarrhea/flushing associated with metastatic carcinoid tumors at doses ≤ 30 mg every 4 wk, our review found that several studies within the published literature described the use of above-label doses of octreotide-LAR for symptom and tumor control of neuroendocrine tumors. Expert clinical opinion, as reported in this review, supports escalation of somatostatin analogs for patients with refractory hormonal symptoms.
Publish Date 2015-02-11 17:56
Citation Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955
Url http://www.wjgnet.com/1007-9327/full/v21/i6/1945.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i6.1945
Full Article (PDF) WJG-21-1945.pdf
Full Article (Word) WJG-21-1945.doc
Manuscript File 10318-Review.doc
Answering Reviewers 10318-Answering reviewers.pdf
Copyright License Agreement 10318-Copyright assignment.pdf
Peer-review Report 10318-Peer review.pdf
Scientific Misconduct Check 10318-CorssCheck.jpg
Scientific Editor Work List 10318-Scientific editor work list.pdf